Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

884
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
884
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

692
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
692
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

631
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
631
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

994
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
994
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

586
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
586
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

1.4K
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preoperative Intravitreal Conbercept Facilitates Vitrectomy in Proliferative Diabetic Retinopathy: Is Attention Required for the Fellow Eye?

Journal of ophthalmology·2019
Same author

Low-dose statin pretreatment reduces stroke severity and improves functional outcomes.

Journal of neurology·2019
Same author

Nanotribological Properties of Ga- and N-Faced Bulk Gallium Nitride Surfaces Determined by Nanoscratch Experiments.

Materials (Basel, Switzerland)·2019
Same author

Genetic Diversity and Population Structure Analysis of Three Deep-Sea Amphipod Species from Geographically Isolated Hadal Trenches in the Pacific Ocean.

Biochemical genetics·2019
Same author

Properties and Reaction Mechanisms of Magnesium Phosphate Cement Mixed with Ferroaluminate Cement.

Materials (Basel, Switzerland)·2019
Same author

Zein Particle-Stabilized Water-In-Water Emulsion as a Vehicle for Hydrophilic Bioactive Compound Loading of Riboflavin.

Journal of agricultural and food chemistry·2019

Related Experiment Video

Updated: Mar 13, 2026

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
10:37

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform

Published on: November 30, 2016

8.7K

RNA interference-based nanosystems for inflammatory bowel disease therapy.

Jian Guo1, Xiaojing Jiang1, Shuangying Gui2

  • 1Department of Pharmaceutics, College of Pharmacy, Anhui University of Chinese Medicine.

International Journal of Nanomedicine
|October 30, 2016
PubMed
Summary

RNA interference (RNAi) offers a precise method to treat inflammatory bowel disease (IBD) by targeting specific genes. Nanovectors enhance RNAi efficacy and safety for potential clinical applications in IBD therapy.

Keywords:
RNA interferenceinflammatory bowel diseasemiRNAnanoparticlessiRNAtarget therapy

More Related Videos

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
07:05

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Published on: December 15, 2017

8.8K
Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

565

Related Experiment Videos

Last Updated: Mar 13, 2026

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform
10:37

Perturbations of Circulating miRNAs in Irritable Bowel Syndrome Detected Using a Multiplexed High-throughput Gene Expression Platform

Published on: November 30, 2016

8.7K
Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
07:05

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Published on: December 15, 2017

8.8K
Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

565

Area of Science:

  • Biotechnology and Nanomedicine
  • Gastroenterology and Immunology

Background:

  • Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn's disease, is a chronic gastrointestinal condition requiring long-term management.
  • Current IBD treatments (anti-inflammatories, glucocorticoids, immunosuppressants) have limitations due to systemic side effects and toxicity.
  • RNA interference (RNAi) presents a targeted approach to modulate IBD-related gene expression and reduce inflammation.

Purpose of the Study:

  • To explore the potential of RNA interference (RNAi) molecules, including short interfering RNA (siRNA) and microRNA (miRNA), for treating inflammatory bowel disease (IBD).
  • To review the development and application of non-viral nanovectors for delivering RNAi molecules.
  • To discuss the challenges and barriers in developing efficient RNAi delivery systems for clinical use in IBD.

Main Methods:

  • Review of RNA interference (RNAi) mechanisms for regulating susceptibility genes in inflammatory bowel disease (IBD).
  • Discussion of nanovector systems designed for the delivery of RNA interference (RNAi) molecules (siRNA and miRNA).
  • Analysis of in vivo degradation, off-target effects, and immunostimulation associated with RNAi therapies.

Main Results:

  • RNA interference (RNAi) can precisely target genes, reducing proinflammatory cytokines and promoting intestinal healing in inflammatory bowel disease (IBD) models.
  • Non-viral nanovectors effectively protect RNAi molecules from degradation and mitigate off-target effects and immunostimulation.
  • Nanovector-based RNAi delivery systems show promise for overcoming current limitations in IBD treatment.

Conclusions:

  • Non-viral nanovectors represent a promising strategy for the safe and effective delivery of RNA interference (RNAi) molecules in inflammatory bowel disease (IBD) therapy.
  • Further development of efficient delivery systems is crucial for the clinical translation of RNAi-based treatments for IBD.
  • Nanoparticle-mediated RNAi holds potential for alleviating IBD progression and restoring intestinal mucosa integrity.